Abstract

Experiments were conducted to determine the ability of the newly discovered ETA receptor antagonist, BQ-123, to inhibit the pressor responses to several members of the human endothelin peptide family in anesthetized rats. Big ET-1 produced a greater increase in mean arterial pressure compared to ET-1 (67 ± 10% vs. 44 ± 4%, p < 0.05; both at 1 nmol/kg i.v.). Prior administration of BQ-123 (10 mg/kg i.v.) was more effective at inhibiting the response to Big ET-1 compared to ET-1. Following ETA receptor blockade, ET-1 produced a small, but significant, increase in mean arterial pressure (15 ± 2%) while Big ET-1 had no effect (5 ± 2%). Big ET-3 and ET-3 at 1 nmol/kg i.v. produced similar increases in mean arterial pressure, although less than that produced by either Big ET-1 or ET-1 (p < 0.05). ETA receptor antagonism blocked 64% of the pressor response to both Big ET-3 and ET-3. We conclude that blockade of pressor responses to each of the endothelin peptides suggests that the increases in arterial pressure ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.